From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors.

Zejula (niraparib) - GSK, J&J

Rubraca (rucaparib) - Pharma& Schweiz

Lynparza (olaparib) - Merck (MSD), AstraZeneca

saruparib (AZD5305) - AstraZeneca

Talzenna (talazoparib) - Pfizer

http://www.ncbi.nlm.nih.gov/pubmed/42568603

Ahmed Malki; Maha M Ayoub; Rafia Anjum; Reem M Alkarbi; Shayma A Osman

Aug 9, 2026